Remove unit-operations
article thumbnail

Harrow agrees to acquire US rights to Novartis’ ophthalmic products

Pharmaceutical Technology

Harrow has signed a binding agreement to acquire exclusive US commercial rights to five ophthalmic products of Novartis. These products, namely, Ilevro, Vigamox, Maxidex, Nevanac and Triesence, have received approval from the Food and Drug Administration (FDA). Outside of the US region, Novartis will have sole rights to the products.

article thumbnail

How single-use technologies can improve antibodies production  

Drug Discovery World

Where the bottlenecks of achieving higher cell density and higher titers were once thought to be issues of the past, hurdles have now shifted to achieving speed and scale in mAb production without sacrificing quality. DC: Antibodies have and remain a large product class within the biopharmaceutical market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK Invests $272 Million in New Vaccine Manufacturing Unit for Production of Shingles and RSV Vaccines

XTalks

GlaxoSmithKline (GSK) has been pumping large sums of cash into expanding its vaccine manufacturing operations and today, it announced an investment of €250 ($272 million) into building a new unit for freeze-drying vaccines at its Wavre campus in Belgium. Both vaccines will be manufactured at the new unit in Belgium. billion ($2.1

article thumbnail

Outsourcing Biologics Fill Finish Manufacturing : Streamlining the Production Process for Biopharmaceutical Companies

Roots Analysis

The production of biologics involves high degree of fragility and sensitivity involving the need for complex manufacturing capabilities, such as fermentation, aseptic fill finish , adequate storage with controlled temperatures and analytical testing to offer quality products.

article thumbnail

The latest drug discovery product launches

Drug Discovery World

Continuous manufacturing (CM) line for oral solids – WuXi STA WuXi STA’s first drug product continuous manufacturing (CM) line for oral solids is in operation at the drug product site in Wuxi city, China. The post The latest drug discovery product launches appeared first on Drug Discovery World (DDW).

article thumbnail

Polar Leasing Validation Reports

Pharmaceutical Commerce

Polar Leasing temperature controlled cold rooms offer accurate temperature control for temperature sensitive product storage. They also provide the flexibility to move the refrigerated unit to various parts of your facility as areas of need change.

article thumbnail

BioNTech to Build First mRNA Vaccine Production Plant in Africa

XTalks

BioNTech has announced plans to build a manufacturing facility in Africa to help ramp up production of COVID-19 mRNA vaccines for countries in the continent. BioNTech will head the construction of the state-of-the-art, end-to-end manufacturing plant with production capacities in accordance with GMP standards.